3,4-dihydroxyphenylacetic acid has been researched along with Huntington Disease in 15 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the BACHD model of Huntington's disease we demonstrate that the vector can be kept in a continuous ON-state for extended periods of time." | 1.48 | Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, S | 1 |
| Tereshchenko, J | 1 |
| Zimmer, V | 1 |
| Vachey, G | 1 |
| Pythoud, C | 1 |
| Rey, M | 1 |
| Liefhebber, J | 1 |
| Raina, A | 1 |
| Streit, F | 1 |
| Mazur, A | 1 |
| Bähr, M | 1 |
| Konstantinova, P | 1 |
| Déglon, N | 1 |
| Kügler, S | 1 |
| Puginier, E | 1 |
| Bharatiya, R | 1 |
| Chagraoui, A | 1 |
| Manem, J | 1 |
| Cho, YH | 1 |
| Garret, M | 1 |
| De Deurwaerdère, P | 1 |
| Renoir, T | 1 |
| Argyropoulos, A | 1 |
| Chevarin, C | 1 |
| Lanfumey, L | 1 |
| Hannan, AJ | 1 |
| Chen, S | 1 |
| Zhang, XJ | 1 |
| Xie, WJ | 1 |
| Qiu, HY | 1 |
| Liu, H | 1 |
| Le, WD | 1 |
| Kraft, JC | 1 |
| Osterhaus, GL | 1 |
| Ortiz, AN | 1 |
| Garris, PA | 1 |
| Johnson, MA | 1 |
| Zádori, D | 1 |
| Geisz, A | 1 |
| Vámos, E | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 2 |
| Lastres-Becker, I | 1 |
| de Miguel, R | 1 |
| De Petrocellis, L | 1 |
| Makriyannis, A | 1 |
| Di Marzo, V | 1 |
| Fernández-Ruiz, J | 2 |
| de Lago, E | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Walsh, FX | 1 |
| Bird, ED | 2 |
| Stevens, TJ | 1 |
| Melamed, E | 1 |
| Hefti, F | 1 |
| Nakazato, T | 1 |
| Akiyama, A | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Dedeoglu, A | 1 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Beal, MF | 1 |
| Rebec, GV | 1 |
| Barton, SJ | 1 |
| Ennis, MD | 1 |
| Garrett, MC | 1 |
| Soares-da-Silva, P | 1 |
| Isacson, O | 1 |
| Brundin, P | 1 |
| Gage, FH | 1 |
| Björklund, A | 1 |
15 other studies available for 3,4-dihydroxyphenylacetic acid and Huntington Disease
| Article | Year |
|---|---|
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression | 2018 |
Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Brain; Disease Models, Animal; Dopamine; D | 2019 |
Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitor | 2014 |
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; DNA | 2015 |
In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Central Nervous System Agents; Chroma | 2009 |
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2009 |
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Can | 2003 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Monoamine transmitters and their metabolites in the basal ganglia of Huntington's disease and control postmortem brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Basal Ganglia; Dopamine; Homovanillic Acid; Humans; Huntington Disea | 1982 |
Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: studies in postmortem tissues and in rats with kainic acid lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Diseases; Corpus Striatum; Dopamine; Female; Homovani | 1982 |
In vivo electrochemical measurement of the long-lasting release of dopamine and serotonin induced by intrastriatal kainic acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Circadian Rhythm; Corpus Striatum; Dopamine; | 1997 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Behavior, Animal; Body Weight; Corpus Striat | 2002 |
Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Biogenic Amines; Brain; Dopamine; Female; Humans; Huntington | 1992 |
Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Choline O-Acetyltransferase; Corpus Striatum; Disease Model | 1985 |